Axonics, Inc. (AXNX)
NASDAQ: AXNX · IEX Real-Time Price · USD
67.09
-0.04 (-0.06%)
May 31, 2024, 4:00 PM EDT - Market closed
Axonics Revenue
Axonics had revenue of $387.14M in the twelve months ending March 31, 2024, with 30.82% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $91.41M with 29.38% year-over-year growth. In the year 2023, Axonics had annual revenue of $366.38M with 33.86% growth.
Revenue (ttm)
$387.14M
Revenue Growth
+30.82%
P/S Ratio
8.84
Revenue / Employee
$485,744
Employees
797
Market Cap
3.42B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 366.38M | 92.68M | 33.86% |
Dec 31, 2022 | 273.70M | 93.41M | 51.81% |
Dec 31, 2021 | 180.29M | 68.76M | 61.64% |
Dec 31, 2020 | 111.54M | 97.72M | 707.05% |
Dec 31, 2019 | 13.82M | 13.11M | 1,854.74% |
Dec 31, 2018 | 707.00K | 579.00K | 452.34% |
Dec 31, 2017 | 128.00K | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Perrigo Company | 4.56B |
Surgery Partners | 2.79B |
Alkermes | 1.73B |
LivaNova | 1.19B |
Tandem Diabetes Care | 770.01M |
Corcept Therapeutics | 523.53M |
Axsome Therapeutics | 251.02M |
PROCEPT BioRobotics | 156.33M |
AXNX News
- 15 days ago - Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia - Business Wire
- 4 weeks ago - Axonics Reports First Quarter 2024 Financial Results - Business Wire
- 5 weeks ago - Boston Scientific Announces Results for First Quarter 2024 - PRNewsWire
- 2 months ago - FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal - Reuters
- 2 months ago - Axonics Stockholders Approve Merger Agreement with Boston Scientific - Business Wire
- 2 months ago - Axonics Provides Update on Inter Partes Review Proceedings - Business Wire
- 2 months ago - Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System - Business Wire
- 3 months ago - Axonics Responds to ITC Action by Medtronic - Business Wire